Korean firms shy of R&D

Published: 2011-09-29 06:59:00

Updated: 2011-09-29 06:59:00

Korean drug firms are showing a negative attitude towards research and development (R&D) due to the government’s plan to cut drug prices by an average of 17 percent starting next year, according to Rep. Choi Young-hee of the main opposition Democratic Party who commissioned the survey with the Ko...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK